IRS1 and Insulin resistance: By measuring the protein levels of insulin resistance markers and evaluating glucose uptake abilities, we confirmed that the improvement of expression levels of IRS-1, GLUT4 (Fig. 4b-d), and glucose uptake ability (Fig. 5, Additional file 1: Figure S1) were significantly reduced after anti-FGF1 neutralizing antibody treatment compare to cAT-MSC CM treated group.